# GPR6

## Overview
GPR6 is a gene that encodes the G protein-coupled receptor 6, a member of the rhodopsin-like Class A GPCR family. This receptor is characterized by its seven transmembrane helices and is predominantly expressed in the central nervous system, particularly in regions such as the striatum and hypothalamus. GPR6 is involved in the regulation of cyclic AMP (cAMP) production due to its constitutive activity as a Gαs-coupled receptor, which plays a crucial role in neuronal development, neurite outgrowth, and neuronal cell survival (Isawi2020GPR6; Laun2024A). The receptor also participates in both G protein-dependent and independent signaling pathways, including the recruitment of β-arrestin2, which underscores its involvement in diverse cellular signaling mechanisms (Isawi2020GPR6). GPR6's activity is linked to learning and memory functions, as well as dopamine signaling and motor control, making it a potential target for therapeutic interventions in neurological disorders such as Parkinson's and Alzheimer's diseases (Shrader2020Discovery; Laun2024A).

## Structure
GPR6 is a G protein-coupled receptor (GPCR) that belongs to the rhodopsin-like Class A GPCR family. It is characterized by seven transmembrane helices, a common feature of GPCRs, and lacks helix kinking proline residues in the second and fifth transmembrane segments (Isawi2020GPR6; Morales2018Towards). The receptor contains conserved motifs such as DRY in TMH3, CWXP in TMH6, and NPXXY in TMH7, which are typical of Class A GPCRs (Morales2018Towards). 

GPR6 has a relatively long N-terminus consisting of 70 amino acids, which may include a helical segment, and an internal disulfide bridge in the second extracellular loop, formed by a CX6CX4P motif (Isawi2020GPR6). The receptor's structure has been modeled using the Sphingosine-1-phosphate receptor 1 (S1P1) as a template, due to its 33% sequence homology with GPR6 (Isawi2020GPR6). This model highlights unique structural features, such as additional helix bending residues in TMH6, including five glycine residues and a threonine (T6.43), which are not present in S1P1 (Isawi2020GPR6). 

The receptor's structure is further stabilized by interactions such as hydrogen bonds and aromatic stacking, which are crucial for its function and ligand binding (Isawi2020GPR6).

## Function
GPR6 is a G protein-coupled receptor (GPCR) that is highly expressed in the central nervous system, particularly in the striatum and hypothalamus. It is involved in the regulation of cyclic AMP (cAMP) production due to its constitutive activity as a Gαs-coupled receptor, which leads to the activation of adenylate cyclase and subsequent cAMP accumulation (Isawi2020GPR6; Laun2024A). This receptor is also capable of signaling through both G protein-dependent and independent pathways, including the recruitment of β-arrestin2, indicating its role in diverse cellular signaling mechanisms (Isawi2020GPR6).

GPR6 plays a significant role in neuronal development and function. It is involved in neurite outgrowth and neuronal cell survival, which are critical for proper neuronal network formation and maintenance (Laun2018GPR3; Laun2024A). The receptor's activity is linked to learning processes, as it regulates cAMP production in striatal medium spiny neurons, which are essential for normal learning and memory functions (Laun2024A). Additionally, GPR6 has been implicated in modulating dopamine signaling and motor activity, suggesting its involvement in motor control and potentially in the pathophysiology of movement disorders (Shrader2020Discovery).

## Clinical Significance
GPR6 is implicated in several neurological conditions due to its role in modulating dopamine signaling and cAMP production. In Alzheimer's disease, GPR6 is upregulated through a C1q-mediated mechanism, providing neuroprotection against amyloid-β-induced neurotoxicity, suggesting its potential role in neuroprotection for Alzheimer's patients (Laun2018GPR3; Laun2024A). In Parkinson's disease, GPR6-deficient mice exhibit increased dopamine concentrations in striatal tissue, decreased cAMP levels, and improved motor activity, indicating that GPR6 could be a novel target for treatment, distinct from traditional dopamine-centric therapies (Isawi2020GPR6; Laun2018GPR3). The pharmaceutical industry is exploring GPR6 inverse agonists, such as pyrazine derivatives, for managing Parkinson's disease symptoms and other dyskinesia syndromes (Isawi2020GPR6).

GPR6 is also involved in instrumental learning, as it regulates cAMP production in striatal medium spiny neurons. GPR6 knockout mice show changes in instrumental conditioning, suggesting its importance in normal learning processes and potential as a target for neuropsychiatric disorders (Laun2018GPR3; Laun2024A). Despite its therapeutic potential, the lack of identified ligands and structural information on GPR6 has hindered its exploitation (Isawi2020GPR6).

## Interactions
GPR6, a G protein-coupled receptor, is involved in various signaling pathways through its interactions with other proteins. It is known to couple with Gs proteins, leading to the activation of adenylyl cyclase and subsequent accumulation of cyclic AMP (cAMP) in neurons (Laun2018Novel). This receptor also engages in G protein-independent signaling pathways, notably involving β-arrestin2, which is recruited constitutively by GPR6, indicating a role in biased signaling mechanisms (Laun2018Novel; Isawi2020GPR6).

GPR6 has been shown to interact with sphingosine-1-phosphate (S1P), a ligand that induces intracellular calcium release and activates the sphingosine-kinase pathway. This interaction is mediated through inhibitory G proteins, as evidenced by the inhibition of signaling in the presence of pertussis toxin (Uhlenbrock2002Sphingosine; Ignatov2003Sphingosine1phosphate). The receptor's activation by S1P also involves the phosphorylation of MAP kinase, contributing to cell survival under stress conditions (Ignatov2003Sphingosine1phosphate).

The structural features of GPR6, such as its transmembrane helices, play a crucial role in its interactions and signaling capabilities. These features include unique residues that influence the receptor's conformation and its ability to transition between active and inactive states (Isawi2020GPR6).


## References


[1. (Shrader2020Discovery) Sarah H. Shrader and Zhao-Hui Song. Discovery of endogenous inverse agonists for g protein-coupled receptor 6. Biochemical and Biophysical Research Communications, 522(4):1041–1045, February 2020. URL: http://dx.doi.org/10.1016/j.bbrc.2019.12.004, doi:10.1016/j.bbrc.2019.12.004. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2019.12.004)

[2. (Ignatov2003Sphingosine1phosphate) Atanas Ignatov, Julia Lintzel, Hans-Jürgen Kreienkamp, and H Chica Schaller. Sphingosine-1-phosphate is a high-affinity ligand for the g protein-coupled receptor gpr6 from mouse and induces intracellular ca2+ release by activating the sphingosine-kinase pathway. Biochemical and Biophysical Research Communications, 311(2):329–336, November 2003. URL: http://dx.doi.org/10.1016/j.bbrc.2003.10.006, doi:10.1016/j.bbrc.2003.10.006. This article has 55 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2003.10.006)

[3. (Laun2018GPR3) Alyssa S. Laun, Sarah H. Shrader, Kevin J. Brown, and Zhao-Hui Song. Gpr3, gpr6, and gpr12 as novel molecular targets: their biological functions and interaction with cannabidiol. Acta Pharmacologica Sinica, 40(3):300–308, June 2018. URL: http://dx.doi.org/10.1038/s41401-018-0031-9, doi:10.1038/s41401-018-0031-9. This article has 95 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41401-018-0031-9)

4. (Laun2024A) A study of GPR3, GPR6, of GPR12 as novel molecular targets for cannabidiol. This article has 1 citations.

[5. (Uhlenbrock2002Sphingosine) Kirsten Uhlenbrock, Hans Gassenhuber, and Evi Kostenis. Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active g protein-coupled receptors. Cellular Signalling, 14(11):941–953, November 2002. URL: http://dx.doi.org/10.1016/s0898-6568(02)00041-4, doi:10.1016/s0898-6568(02)00041-4. This article has 168 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0898-6568(02)00041-4)

[6. (Laun2018Novel) Alyssa S. Laun, Sarah H. Shrader, and Zhao-Hui Song. Novel inverse agonists for the orphan g protein-coupled receptor 6. Heliyon, 4(11):e00933, November 2018. URL: http://dx.doi.org/10.1016/j.heliyon.2018.e00933, doi:10.1016/j.heliyon.2018.e00933. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.heliyon.2018.e00933)

[7. (Morales2018Towards) Paula Morales, Israa Isawi, and Patricia H. Reggio. Towards a better understanding of the cannabinoid-related orphan receptors gpr3, gpr6, and gpr12. Drug Metabolism Reviews, 50(1):74–93, January 2018. URL: http://dx.doi.org/10.1080/03602532.2018.1428616, doi:10.1080/03602532.2018.1428616. This article has 39 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/03602532.2018.1428616)

[8. (Isawi2020GPR6) Israa H. Isawi, Paula Morales, Noori Sotudeh, Dow P. Hurst, Diane L. Lynch, and Patricia H. Reggio. Gpr6 structural insights: homology model construction and docking studies. Molecules, 25(3):725, February 2020. URL: http://dx.doi.org/10.3390/molecules25030725, doi:10.3390/molecules25030725. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/molecules25030725)